tesaglitazar has been researched along with warfarin in 4 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (warfarin) | Trials (warfarin) | Recent Studies (post-2010) (warfarin) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 36,573 | 2,143 | 14,728 |
| Protein | Taxonomy | tesaglitazar (IC50) | warfarin (IC50) |
|---|---|---|---|
| Vitamin K epoxide reductase complex subunit 1 | Homo sapiens (human) | 0.0088 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Amaudrut, J; Barth, M; Binet, J; Boubia, B; Broqua, P; Chatar, M; Dodey, P; Ferry, S; Gauthier, E; Guillier, F; Jacquier, E; Junien, JL; Lacombe, O; Legendre, C; Lepais, V; Llacer, J; Luccarini, JM; Masson, P; Montalbetti, C; Mounier, L; Peralba, P; Poupardin, O; Thourigny, A; Wettstein, G | 1 |
4 other study(ies) available for tesaglitazar and warfarin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Topics: Animals; Benzothiazoles; Carbon Tetrachloride Poisoning; Cell Line; Drug Discovery; Fibrosis; Hepatocytes; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Indoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 2018 |